Anu Wallecha

Summary

Publications

  1. ncbi Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy
    Anu Wallecha
    Research and Development, Advaxis Inc, 675 US Highway One, Suite 120, Technology Center of New Jersey, North Brunswick, NJ 08902, USA
    Clin Vaccine Immunol 16:96-103. 2009
  2. ncbi Development of a Listeria monocytogenes based vaccine against prostate cancer
    Vafa Shahabi
    Research and Development, Advaxis, Inc, North Brunswick, NJ, USA
    Cancer Immunol Immunother 57:1301-13. 2008
  3. ncbi Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment
    Vafa Shahabi
    Advaxis Inc, Research and Development, North Brunswick, NJ, USA
    Bioeng Bugs 1:235-43. 2010
  4. ncbi Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic
    Reshma Singh
    Research and Development, Advaxis Inc, North Brunswick, NJ, USA
    Hum Vaccin 7:497-505. 2011

Detail Information

Publications4

  1. ncbi Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy
    Anu Wallecha
    Research and Development, Advaxis Inc, 675 US Highway One, Suite 120, Technology Center of New Jersey, North Brunswick, NJ 08902, USA
    Clin Vaccine Immunol 16:96-103. 2009
    ....
  2. ncbi Development of a Listeria monocytogenes based vaccine against prostate cancer
    Vafa Shahabi
    Research and Development, Advaxis, Inc, North Brunswick, NJ, USA
    Cancer Immunol Immunother 57:1301-13. 2008
    ..Together, these results indicate that Lm-LLO-PSA is a potential candidate for pCa immunotherapy and should be further developed...
  3. ncbi Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment
    Vafa Shahabi
    Advaxis Inc, Research and Development, North Brunswick, NJ, USA
    Bioeng Bugs 1:235-43. 2010
    ..The present paper includes a review of the most recent advances in the development of these two bacterial vectors for treatment of cancer. Similarities and differences between the two vectors are discussed...
  4. ncbi Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic
    Reshma Singh
    Research and Development, Advaxis Inc, North Brunswick, NJ, USA
    Hum Vaccin 7:497-505. 2011
    ..Additional data on the efficacy of these vaccines is expected in the near-term...